EUCTR2014-005053-40-Outside-EU/EEA进行中（未招募）不适用
A Phase III, Observer-Blind, Randomized, Multi-center Study to Evaluate the Safety, Tolerability, and Immunogenicity of Fluad and Agriflu Compared to the Non Adjuvanted Trivalent Influenza Vaccine Fluzone in Children 6 to <72 Months of Age.
ovartis Vaccines and Diagnostics S.r.l0 个研究点目标入组 5,750 人开始时间: 2014年11月25日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 5,750
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Children 6 months to 72 months of age
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 5750
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Who had been hospitalized at the time of enrollment
- •2.Who had any serious reaction or hypersensitivity to any vaccine component, eggs, or chicken protein
- •3.Who had known impairment of the immune function
- •4.Who had fever interfering with normal daily activities at the time of enrollment
- •5.Who had received licensed vaccines within 14 days (for inactivated vaccines) or 28 days (for live vaccines) prior to enrollment in the study
- •6.Concomitant participation in another clinical study
- •7.Who had surgery planned during the study period that in the investigator's opinion would have interfered with the study visits schedule.
研究者
相似试验
进行中（未招募）
不适用
A study to determine the immunogenicity and safety profile of CSL Limited's Influenza Virus Vaccine compared to a US licensed comparator Influenza Virus Vaccine in a pediatric population aged greater than or equal to 6 months to less than 18 years.Influenza, humanEUCTR2014-003768-19-Outside-EU/EEACSL Limited1,350
进行中（未招募）
不适用
A phase III, randomized, observer blind, multi-centre study to evaluate the immunogenicity, safety and reactogenicity of study vaccine GSK1557482A (FluLaval thiomersal-free), Fluarix and FluLaval thiomersal-containing vaccines in young adult (18 to 60 years) and elderly subjects (over 60 years) - FLU-Q-TIV-TF-003 PRIEUCTR2008-001445-26-EEGlaxoSmithKline Biologicals1,540
进行中（未招募）
1 期
Study to assess the immunogenicity and safety of GSK's meningococcal group B vaccine when administered concomitantly with GSK's meningococcal MenACWY conjugate vaccine in healthy subjects of 16-18 years of age.Active immunization against invasive meningococcal disease caused by 5 different serogroups of N. meningitidis by concomitant administration of meningococcal group B vaccine and meningococcal MenACWY conjugate vaccineMedDRA version: 20.0Level: PTClassification code 10027199Term: MeningitisSystem Organ Class: 10021881 - Infections and infestationsEUCTR2016-003722-16-ITGLAXOSMITHKLINE BIOLOGICALS945
进行中（未招募）
1 期
A study to evaluate the immunogenicity and safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a pediatric population aged 5 through to 17 years of ageProphylaxis for influenza virus infectionMedDRA version: 19.0Level: PTClassification code 10022000Term: InfluenzaSystem Organ Class: 10021881 - Infections and infestationsEUCTR2016-004133-25-Outside-EU/EEASeqirus GmbH2,222
招募中
1 期
A Phase 3/3b, Randomized, Observer-blind, Multicenter Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Quadrivalent Influenza Vaccine in Adults =65 Years of AgeInfluenza virusMedDRA version: 20.0Level: PTClassification code: 10022000Term: Influenza Class: 100000004862CTIS2022-503004-24-00Seqirus UK Limited35,800